睿知中国医院研究地图
候选清单

正在招募乳腺癌未注明分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07653893,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Cohort 2 (Experimental Cohort): Presence of brain parenchymal metastases confirmed by contrast-enhanced brain MRI, with at least one measurable brain lesion not previously irradiated, evaluable per RECIST 1.1 criteria.

    入选标准第 3 条

  3. Patients receiving mannitol, steroids, or anticonvulsant therapy prior to the first dose are eligible if the drug doses are stable for at least one week without requiring an increase, and neurological symptoms are stable for ≥1 week.

    入选标准第 4 条

    Previous treatment with an anti-HER2 ADC drug carrying the same payload resulting in resistance. Patients who discontinued prior ADC therapy for other reasons, including but not limited to toxicity, are eligible.

    排除标准第 2 条

  4. 1. ≥18 years(2007-06), any gender. 2. ECOG Performance Status 0-2. 3. Evidence of local recurrence or metastatic breast cancer not amenable to curative surgery or radiotherapy, and planned for intravenous trastuzumab deruxtecan treatment.

    入选标准第 1 条

  5. ANC≥1.5×109/L;

    入选标准第 7 条

    Hb≥90 g/L (allowing blood transfusion or medication to ensure hemoglobin content);

    入选标准第 9 条

    Coagulation function: APTT≤1.5×ULN;PT≤1.5×ULN;

    入选标准第 10 条

    TBIL≤1.5×ULN;

    入选标准第 12 条

    ALT and AST≤3×ULN (≤ 5.0×ULN for liver metastases);

    入选标准第 13 条

    Creatinine ≤1.5 × ULN or Creatinine Clearance ≥50 mL/min (Cockcroft-Gault formula);

    入选标准第 14 条

  6. History of other malignancies within the past 5 years, excluding cured carcinoma in situ of the cervix, basocellular skin carcinomas, or cutaneous squamous cell carcinoma.

    排除标准第 4 条

    HIV infection, active HBV or HCV infection. The following exceptions are allowed:

    排除标准第 12 条

    Hepatitis C (HCV) antibody-positive patients who are HCV RNA-negative. 8. History of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, or glomerulonephritis, except for autoimmune thyroid dysfunction treated with stable-dose hormone replacement therapy.

    排除标准第 14 条

  7. Inability to cooperate with lumbar puncture. 11. Vaccination with any vaccine within 28 days prior to the first dose. 12. Pregnant or lactating female patients; female patients of childbearing potential with baseline pregnancy test positive; or patients unwilling to use effective contraception throughout the trial period.

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07653893,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1. ≥18 years(2007-06), any gender. 2. ECOG Performance Status 0-2. 3. Evidence of local recurrence or metastatic breast cancer not amenable to curative surgery or radiotherapy, and planned for intravenous trastuzumab deruxtecan treatment.
  2. Expected survival time ≥8 weeks. 5. Provision of sufficient fresh tissue specimen or ≥10 unstained slides of tumor sample (primary and/or metastatic site) for biomarker analysis prior to treatment (intracranial metastatic lesion specimens preferred).
  3. Cohort 2 (Experimental Cohort): Presence of brain parenchymal metastases confirmed by contrast-enhanced brain MRI, with at least one measurable brain lesion not previously irradiated, evaluable per RECIST 1.1 criteria.
  4. Patients receiving mannitol, steroids, or anticonvulsant therapy prior to the first dose are eligible if the drug doses are stable for at least one week without requiring an increase, and neurological symptoms are stable for ≥1 week.
  5. Organ function levels must meet the following requirements:
  6. Hematology:
  7. ANC≥1.5×109/L;
  8. PLT≥75×109/L;
  9. Hb≥90 g/L (allowing blood transfusion or medication to ensure hemoglobin content);
  10. Coagulation function: APTT≤1.5×ULN;PT≤1.5×ULN;
  11. Blood Chemistry:
  12. TBIL≤1.5×ULN;
  13. ALT and AST≤3×ULN (≤ 5.0×ULN for liver metastases);
  14. Creatinine ≤1.5 × ULN or Creatinine Clearance ≥50 mL/min (Cockcroft-Gault formula);
  15. Cardiac Ultrasound: LVEF ≥50%;
  16. 12-Lead ECG: Fridericia-corrected QT interval (QTcF) <470 ms for females, <450 ms for males; 9. Voluntary participation in this study, signed informed consent, good compliance, and willingness to cooperate with follow-up.

排除标准:Exclusion Criteria:

  1. 1. Presence of uncontrolled third-space fluid accumulation (e.g., large pleural effusion or ascites) not manageable by drainage or other methods, deemed unsuitable for enrollment by the investigator.
  2. Previous treatment with an anti-HER2 ADC drug carrying the same payload resulting in resistance. Patients who discontinued prior ADC therapy for other reasons, including but not limited to toxicity, are eligible.
  3. Adverse reactions from prior anti-tumor therapy have not recovered to ≤ Grade 1 per CTCAE v5.0 (except for ≤ Grade 2 toxicities judged by the investigator as having no safety risk, such as alopecia or long-term toxicities from radiotherapy).
  4. History of other malignancies within the past 5 years, excluding cured carcinoma in situ of the cervix, basocellular skin carcinomas, or cutaneous squamous cell carcinoma.
  5. History of severe cardiovascular or cerebrovascular diseases, including but not limited to:
  6. Severe cardiac rhythm or conduction abnormalities requiring clinical intervention, such as ventricular arrhythmia, II-III degree atrioventricular block, etc.
  7. Cardiac insufficiency of Class III\~IV according to the New York Heart Association (NYHA) criteria.
  8. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade 3 or higher cardiovascular/cerebrovascular events within 6 months prior to the first dose.
  9. Clinically uncontrolled hypertension.
  10. Any factors increasing the risk of QTc prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, use of any concomitant medications known or suspected to prolong the QT interval; Known history of allergy to any component of the study drug.
  11. History of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, history of organ transplantation, allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation.
  12. HIV infection, active HBV or HCV infection. The following exceptions are allowed:
  13. Patients positive for hepatitis B surface antigen (HBsAg), with or without positive hepatitis B core antibody (anti-HBc), if HBV DNA < 1000 IU/mL or below the lower limit of detection at the research center, and per investigator assessment excluding active infection based on clinical treatment and presentation.
  14. Hepatitis C (HCV) antibody-positive patients who are HCV RNA-negative. 8. History of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, or glomerulonephritis, except for autoimmune thyroid dysfunction treated with stable-dose hormone replacement therapy.
  15. Patients with known idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, interstitial lung disease, severe radiation pneumonitis, or evidence of active pneumonia on screening chest CT scan.
  16. Inability to cooperate with lumbar puncture. 11. Vaccination with any vaccine within 28 days prior to the first dose. 12. Pregnant or lactating female patients; female patients of childbearing potential with baseline pregnancy test positive; or patients unwilling to use effective contraception throughout the trial period.
  17. Presence of any concomitant disease, per investigator judgment, that seriously endangers the patient's safety or affects the patient's ability to complete the study (including but not limited to severe hypertension that cannot be controlled by medication, severe diabetes, active infection, thyroid disease, etc.).
  18. Any other circumstances where the researcher deems the patient unsuitable for participation in this study.

引自 ClinicalTrials.gov, NCT07653893, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07653893,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07653893